Ones To Watch News
Refine Search
Pharmaceutical
Shares in US CNS specialist Intra-Cellular Therapies closed 23% higher on Tuesday. 17 April 2024
Biotechnology
A change of therapeutic focus, a full rebrand and a major cash injection will shake things up considerably at Massachusetts, USA-based Cullinan Therapeutics. 17 April 2024
Biotechnology
Innovio Pharmaceuticals has announced plans to raise $36 million in a share sale. 16 April 2024
Pharmaceutical
France-based Medincell, a biopharma developing long-acting injectable drugs in many therapeutic areas, has announced a collaboration with US drugmaker AbbVie. 16 April 2024
Biotechnology
US biotech Arrowhead Pharmaceuticals recently unveiled final data from its Phase II SHASTA-2 clinical trial for plozasiran, previously recognized as ARO-APOC3. 16 April 2024
Pharmaceutical
USA-based rare seizure specialist Marinus Pharmaceuticals saw its shares crash, falling nearly 83% to $1.36, after it revealed that a trial failed to meet early stopping criteria. 16 April 2024
Biotechnology
US immuno-oncology company Portage Biotech has only around a fifth of its stock market value since early Friday, when the firm reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its cash runway. 15 April 2024
Biotechnology
The Phase I trial of NMRA-266 has been placed on clinical hold by the US Food and Drug Administration (FDA), said the drug’s developer, Massachusetts, USA-based based brain disease biotech Neumora Therapeutics. 15 April 2024
Biotechnology
French biotech MaaT Pharma (Euronext: MAAT) today announced positive 18-month data for its lead hemato-oncology candidate MaaT013. 15 April 2024
Biotechnology
Adaptimmune Therapeutics saw its shares close down more than 10% at $1.16, after it disclosed that Roche (ROG: SIX) subsidiary Genentech has terminated their strategic collaboration entered into in 2021., 13 April 2024
Biotechnology
Eliem Therapeutics has raised $120 million in a private share placement and agreed to merge with Tenet Medicines. 12 April 2024
Pharmaceutical
USA-based Nectero Medical has raised $96 million in a Series D financing round led by Norwest Venture Partners, with significant investments also from Boston Scientific, BioStar Capital and others. 12 April 2024
Biotechnology
US biotech Century Therapeutics has announced three news updates in a single day. 11 April 2024
Biotechnology
Adding another Big Pharma to its licensing deals, US biotech Arvinas today announced it has entered an exclusive strategic license agreement with Swiss pharma giant Novartis. 11 April 2024
Biotechnology
Shares of Seattle, USA-based biotech Alpine Immune Sciences 20% on a takeover rumor by Bloomberg, and leapt a further 36% pre-market to $64.10 when the speculation was confirmed. 11 April 2024
Pharmaceutical
Data from the RESMAIN study of Kinselby (resminostat) have been presented at the 5th World Congress of Cutaneous Lymphomas (5WCCL), at the City of Hope, Pasadena, California, USA. 11 April 2024
Biotechnology
The US Food and Drug Administration has given a green light to BrainStorm Cell Therapeutics for the design of a Phase IIIb trial of NurOwn (MSC-NTF cells). 10 April 2024
Biotechnology
Los Angeles, USA-based TORL BioTherapeutics, a biotech focused on discovering and developing antibody-based immunotherapies, has closed an oversubscribed $158 million Series B-2 financing. 10 April 2024
Pharmaceutical
A private share placement is set to land Massachusetts, USA-based Acrivon Therapeutics with an additional $130 million to fund its oncology research. 10 April 2024
Biotechnology
Swiss inflammatory diseases specialist MoonLake Immunotherapeutics has teamed up with US tech platform company Komodo Health. 10 April 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze